Literature DB >> 12554947

Crystallization and preliminary X-ray analysis of recombinant human acid beta-glucocerebrosidase, a treatment for Gaucher's disease.

Dana Roeber1, Aniruddha Achari, Partha Manavalan, Tim Edmunds, David L Scott.   

Abstract

Acid beta-glucocerebrosidase (N-acylsphingosyl-1-O-beta-D-glucoside:glucohydrolase) is a lysosomal glycoprotein that catalyzes the hydrolysis of the glycolipid glucocerebroside to glucose and ceramide. Inadequate levels of this enzyme underly the pathophysiology of Gaucher's disease. Cerezyme (Genzyme Corporation, Cambridge, MA, USA) is a partially deglycosylated form of recombinant human acid beta-glucocerebrosidase that is used in the treatment of Gaucher patients. Although acid beta-glucocerebrosidase belongs to a large family of glycosidases, relatively little is known regarding its structural biology. Here, the crystallization and the initial diffraction analysis of Cerezyme are reported. The crystals are C-centered orthorhombic, with unit-cell parameters a = 285.0, b = 110.2, c = 91.7 A. A 99.9% complete data set has been collected to 2.75 A with an R(sym) of 8.8%.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12554947     DOI: 10.1107/s0907444902020498

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  2 in total

1.  Paenibacillus sp. TS12 glucosylceramidase: kinetic studies of a novel sub-family of family 3 glycosidases and identification of the catalytic residues.

Authors:  Krisztina Paal; Makoto Ito; Stephen G Withers
Journal:  Biochem J       Date:  2004-02-15       Impact factor: 3.857

2.  X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease.

Authors:  Hay Dvir; Michal Harel; Andrew A McCarthy; Lilly Toker; Israel Silman; Anthony H Futerman; Joel L Sussman
Journal:  EMBO Rep       Date:  2003-07       Impact factor: 8.807

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.